AYTU · Aytu Biopharma, Inc
$2.16
+0.00 (+0.00%)
At close · Jul 24
Market Cap
$23.18M
Shares
10.73M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$66.38M
+1.8%
FY2025
Net Income
-$13.56M
+14.4%
FY2025
Gross Margin
69.04%
-6.2pp
FY2025
Operating Margin
-11.79%
-9.4pp
FY2025
Diluted EPS
-$5.11
+93.1%
FY2023
Operating Cash Flow
-$1.94M
-39.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $56.6M | $66.38M | $65.18M | $107.4M | $96.67M | $65.63M | $27.63M | $7.32M | $3.66M | $3.22M | $2.56M | $261.78K | $58.93K | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$114.99K | -$45.55K | — | — | |
| $19.94M | $20.55M | $16.13M | $40.77M | $44.39M | $36.43M | $8.28M | $2.2M | $2.05M | $1.42M | $957.08K | $88.11K | — | — | — | |
| $36.66M | $45.83M | $49.05M | $66.63M | $52.28M | $29.2M | $19.35M | — | — | — | — | — | — | — | — | |
| — | 69.04% | 75.26% | 62.04% | 54.08% | 44.49% | 70.03% | — | — | — | — | — | — | — | — | |
| $216K | $1.33M | $2.77M | $4.1M | $12.66M | $5.62M | $1.72M | $589.07K | $167.6K | $959.86K | $6.13M | $3.22M | $3.93M | — | — | |
| $22.03M | $20.91M | $22.08M | $41.45M | $38.71M | $30.31M | $11.4M | — | — | — | — | — | — | — | — | |
| $18.66M | $17.38M | $19.95M | $28.63M | $31.17M | $25.5M | $19.66M | — | — | — | — | $4.38M | $2.35M | $341.52K | $311.62K | |
| $51.14M | — | — | — | — | — | $34.8M | $18.89M | $17.73M | $17.44M | $8.52M | $3.98M | — | — | — | |
| $2.65M | $3.68M | $3.68M | $4.79M | $5.84M | $6.01M | $4.49M | $2.14M | $1.55M | $1.71M | $664.71K | $90.66K | $70K | — | — | |
| — | $5.38M | $8.27M | $8.82M | $10.15M | $9.2M | $5.71M | $2.73M | $2.59M | $4.36M | $874.79K | $118.2K | $97.48K | $58.35K | — | |
| $0 | $2.1M | $2.16M | $0 | $0 | $4.89M | $667K | — | — | $1507 | $0 | — | — | — | — | |
| $51.82M | $53.66M | $50.65M | $83.7M | $162.19M | $88.07M | $40.48M | $24.17M | $23.36M | $23.35M | $24.27M | $7.89M | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $548.53K | $494.37K | |
| -$15.16M | -$7.83M | -$1.59M | -$17.07M | -$109.91M | -$58.87M | -$21.13M | -$16.85M | -$19.7M | -$20.13M | -$21.7M | -$7.63M | -$6.35M | -$543.28K | -$490.87K | |
| — | -11.79% | -2.44% | -15.89% | -113.69% | -89.7% | -76.47% | -230.13% | -538.24% | -624.7% | -847.02% | -2915.53% | -10770.31% | — | — | |
| — | -$2.45M | $6.68M | -$8.25M | -$99.76M | -$49.67M | -$15.42M | -$14.12M | -$17.11M | -$15.76M | -$20.83M | -$7.51M | -$6.25M | -$484.93K | — | |
| $2.24M | $3.7M | $5.06M | $4.96M | — | — | $2.61M | $535.5K | $749.42K | $2.53M | $5.49M | $114.99K | — | $25.2K | $20.29K | |
| -$690K | -$512K | $870K | $14K | $1.02M | $840K | $7.51M | -$10.29M | $9.51M | -$2.38M | -$6.48M | -$114.99K | — | -$24.92K | -$20.02K | |
| — | — | — | — | — | — | — | — | — | -$61.52K | -$971.63K | — | — | — | — | |
| -$33.67M | -$13.75M | -$10.38M | -$17.05M | -$108.89M | -$58.03M | -$13.62M | — | — | — | -$28.18M | -$7.75M | -$6.39M | — | — | |
| $447K | $437K | $2.14M | $0 | -$110K | $259K | $0 | $0 | $0 | $0 | $0 | -$23.91K | -$813.7K | — | — | |
| -$34.06M | -$13.56M | -$15.84M | -$17.05M | -$108.78M | -$58.29M | -$13.62M | -$27.13M | -$10.19M | -$22.51M | -$28.18M | -$7.72M | -$5.58M | -$568.2K | -$510.89K | |
| — | -20.43% | -24.31% | -15.88% | -112.53% | -88.81% | -49.29% | -370.64% | -278.35% | -698.67% | -1099.73% | -2950.32% | -9466.8% | — | — | |
| USD/shares | — | -$2.16 | -$2.86 | -$5.11 | -$74.01 | -$69.60 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | — | -$5.11 | -$74.01 | -$69.60 | — | — | — | — | — | — | — | — | — |
| shares | — | 6.28M | 5.54M | 3.34M | 1.47M | 837.33K | 225.96K | 38.97K | 3328.025 | 2330.12 | 435.285 | 3836.63 | 34.75K | 24.42K | — |
| shares | — | — | — | 3.34M | 1.47M | 837.33K | 225.96K | 38.97K | 3328.025 | 2330.12 | 435.285 | 3836.63 | 34.75K | 24.42K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.14×
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.34×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.32×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Rx Segment | $66,382,000 | $65,183,000 | $73,799,000 | — | — | — |
| Aytu Bio Pharma | — | — | — | — | — | $17,249,000 |
| Aytu Consumer Health | — | — | — | — | — | $10,383,000 |
| Biopharma | — | — | — | — | $32,678,000 | — |
| Consumer Health | — | — | $33,600,000 | $35,548,000 | $32,954,000 | — |
| Rx | — | — | — | $61,121,000 | — | — |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| United States | $80,911,000 | $106,918,000 | $94,606,000 | $60,687,000 | $24,980,000 |
| Non Us | $91,000 | $481,000 | $2,063,000 | $4,945,000 | $2,652,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| ADHD Portfolio | $57,576,000 | $57,784,000 | — | — | — | — |
| The Pediatric Portfolio | $8,769,000 | $7,280,000 | — | — | — | — |
| Product And Service Other | $37,000 | $119,000 | — | — | — | — |
| Attention Deficit Hyperactivity Disorder Portfolio | — | — | $46,855,000 | $42,855,000 | $10,883,000 | — |
| Consumer Health Portfolio | — | — | — | $35,548,000 | $32,954,000 | $10,383,000 |
| Other Product Portfolio | — | — | — | $2,182,000 | $9,358,000 | — |
| Pediatric Portfolio | — | — | $25,377,000 | $16,084,000 | $12,437,000 | $9,292,000 |
| Primary Care and Devices Legacy | — | — | — | — | — | $7,957,000 |
| Manufactured Product Other | — | — | $1,567,000 | $2,182,000 | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Rx Segment | -$1,590,000 | -$7,358,000 | — |
| Consumer Health | -$3,664,000 | -$9,707,000 | -$17,465,000 |
| Rx | — | — | -$92,441,000 |
Operating Margin by Segment (%)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Rx Segment | -2.4% | -10% | — |
| Consumer Health | — | -28.9% | -49.1% |
| Rx | — | — | -151.2% |